{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:48Z","timestamp":1764510528844},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NCI","award":["1UH2TR00943-01","1 R01 CA182905-01"],"award-info":[{"award-number":["1UH2TR00943-01","1 R01 CA182905-01"]}]},{"name":"UT MD Anderson Cancer Center SPORE in Melanoma","award":["P50 CA093459"],"award-info":[{"award-number":["P50 CA093459"]}]},{"name":"Developmental Research Award","award":["P50 CA100632"],"award-info":[{"award-number":["P50 CA100632"]}]},{"name":"Miriam and Jim Mulva research funds, the Brain","award":["2P50CA127001"],"award-info":[{"award-number":["2P50CA127001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminoncol.2016.02.015","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T18:04:38Z","timestamp":1454954678000},"page":"209-214","source":"Crossref","is-referenced-by-count":31,"title":["MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?"],"prefix":"10.1053","volume":"43","author":[{"given":"Katrien","family":"Van Roosbroeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Calin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.02.015_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/erm.12.134","article-title":"miRNAs and long noncoding RNAs as biomarkers in human diseases","volume":"13","author":"Van Roosbroeck","year":"2013","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3322\/caac.21244","article-title":"MicroRNAome genome: a treasure for cancer diagnosis and therapy","volume":"64","author":"Berindan-Neagoe","year":"2014","journal-title":"Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib3","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib5","first-page":"6640","article-title":"Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene","volume":"61","author":"Bullrich","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib6","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1182\/blood.V99.11.4116","article-title":"Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia","volume":"99","author":"Mertens","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib7","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V97.7.2098","article-title":"Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia","volume":"97","author":"Migliazza","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib8","first-page":"55","article-title":"Comprehensive analysis of a large genomic sequence at the putative B-cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus","volume":"458","author":"Rondeau","year":"2001","journal-title":"Mutat Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib9","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib10","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/cdd.2014.87","article-title":"Role of miR-15\/16 in CLL","volume":"22","author":"Pekarsky","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib12","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1182\/blood-2009-07-192740","article-title":"Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes","volume":"114","author":"Calin","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib13","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1158\/1078-0432.CCR-13-2497","article-title":"microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters","volume":"20","author":"Negrini","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib14","first-page":"115","article-title":"Chronic lymphocytic leukemia: prognostic factors and impact on treatment","volume":"11","author":"Parker","year":"2011","journal-title":"Disc Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3109\/10428194.2013.829919","article-title":"The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia","volume":"55","author":"Stankovic","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib16","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1158\/0008-5472.CAN-07-1585","article-title":"MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth","volume":"67","author":"Corney","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4614-8051-8_14","article-title":"miR deregulation in CLL","volume":"792","author":"Balatti","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4161\/epi.28603","article-title":"microRNA-34b\/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia","volume":"9","author":"Deneberg","year":"2014","journal-title":"Epigenetics"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1479-5876-12-52","article-title":"Epigenetic inactivation of mir-34b\/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia","volume":"12","author":"Wang","year":"2014","journal-title":"J Translat Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2010.1919","article-title":"Association of a microRNA\/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia","volume":"305","author":"Fabbri","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib21","doi-asserted-by":"crossref","first-page":"978312","DOI":"10.1155\/2011\/978312","article-title":"Recent advances in p53 research and cancer treatment","volume":"2011","author":"Suzuki","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2008.377","article-title":"miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities","volume":"23","author":"Mraz","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood-2010-01-263889","article-title":"microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival","volume":"116","author":"Rossi","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib25","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1073\/pnas.1500010112","article-title":"TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia","volume":"112","author":"Balatti","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/2211536602666131126002337","article-title":"MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia","volume":"2","author":"Bottoni","year":"2014","journal-title":"MicroRNA"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2362.2009.02146.x","article-title":"Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12","volume":"39","author":"Porpaczy","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib28","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2009-06-229211","article-title":"Karyotype-specific microRNA signature in chronic lymphocytic leukemia","volume":"114","author":"Visone","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.leu.2405022","article-title":"Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis","volume":"22","author":"Marton","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2119\/molmed.2013.00005","article-title":"Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia","volume":"19","author":"Papakonstantinou","year":"2013","journal-title":"Mol Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib33","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2006-12-062398","article-title":"Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia","volume":"109","author":"Fulci","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.leukres.2010.11.005","article-title":"Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia","volume":"35","author":"Zhu","year":"2011","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib35","doi-asserted-by":"crossref","first-page":"e16956","DOI":"10.1371\/journal.pone.0016956","article-title":"MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells","volume":"6","author":"Li","year":"2011","journal-title":"PloS One"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib36","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/blood-2008-11-189407","article-title":"microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification","volume":"113","author":"Stamatopoulos","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3109\/10428194.2011.642303","article-title":"MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia","volume":"53","author":"Zhou","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","article-title":"miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1","volume":"124","author":"Mraz","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib39","doi-asserted-by":"crossref","unstructured":"Stamatopoulos B, Van Damme M, Crompot E, et al. Opposite prognostic significance of cellular and serum circulating microRNA-150 in Chronic Lymphocytic Leukemia patients. Mol Med 2015;21:123-33","DOI":"10.2119\/molmed.2014.00214"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib40","first-page":"5","article-title":"A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients","author":"Stamatopoulos","year":"2010","journal-title":"PloS One"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib41","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1073\/pnas.1019557108","article-title":"MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia","volume":"108","author":"Moussay","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib42","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2013-01-478222","article-title":"Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia","volume":"122","author":"Ferrajoli","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib43","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib44","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2008-08-172254","article-title":"miR-34a as part of the resistance network in chronic lymphocytic leukemia","volume":"113","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib45","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2009-07-234823","article-title":"microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia","volume":"115","author":"Asslaber","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.18632\/oncotarget.448","article-title":"MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia","volume":"3","author":"Visone","year":"2012","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1476-4598-9-115","article-title":"Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia","volume":"9","author":"Moussay","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib48","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/carcin\/bgs179","article-title":"miR-181a\/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes","volume":"33","author":"Zhu","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4149\/neo_2014_032","article-title":"miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies","volume":"61","author":"Jurkovicova","year":"2014","journal-title":"Neoplasma"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/etm.2014.1752","article-title":"miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy","volume":"8","author":"Chen","year":"2014","journal-title":"Exp Ther Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib51","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s13277-015-3263-z","article-title":"Role of miR-155 in drug resistance of breast cancer","volume":"36","author":"Yu","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1078-0432.CCR-12-1922","article-title":"In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors","volume":"19","author":"Fonte","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-4598-9-123","article-title":"MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia","volume":"9","author":"Ferracin","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Ann Rev Med"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib55","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jcb.24038","article-title":"Non-coding RNAs as theranostics in human cancers","volume":"113","author":"Redis","year":"2012","journal-title":"J Cellular Biochem"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib56","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib57","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: how a complex biology gets more complex","volume":"29","author":"Musilova","year":"2015","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200C","author":"Wicki","year":"2015","journal-title":"J Controlled Release"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib59","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: a new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"miR-34 - a microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Frontiers Genet"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib61","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.4161\/cc.9.14.12267","article-title":"Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia","volume":"9","author":"Merkel","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib62","doi-asserted-by":"crossref","unstructured":"Bader AG, Daige CL, Kelnar K, et al. Preclinical data of a microRNA-based therapy for hepatocellular carcinoma. Annual AACR Conference, Chicago, IL; 2012.","DOI":"10.1158\/1538-7445.AM2012-5636"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib63","doi-asserted-by":"crossref","unstructured":"Daige CL, Priddy L, Kelnar K, et al. The development of a miRNA-based therapeutic candidate for hepatocellular carcinoma. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA; 2011.","DOI":"10.1158\/1535-7163.TARG-11-C142"},{"key":"10.1053\/j.seminoncol.2016.02.015_bib64","unstructured":"Mirna Therapeutics presents interim phase 1 data on first-in-class microRNA-34 mimic, MRX34, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. http:\/\/www.mirnarx.com. Accessed March 10, 2015."},{"key":"10.1053\/j.seminoncol.2016.02.015_bib65","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541600021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541600021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:15:34Z","timestamp":1718349334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377541600021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S009377541600021X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.015","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}